Journal of gastric cancer · 2026
Prognostic Model for Survival After Upfront R0 Gastrectomy in Peritoneal Oligometastatic Gastric Cancer.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Seungho, Roh Yun Ho, Shin Ho-Jung, Song Jeong Ho, Kim Sung Eun, Lee In-Seob, Lee Han Hong, Jeong Oh, Jung Mi Ran, Hur Hoon, Jee Ye Seob, Kim Hyoung-Il
Аннотация
PURPOSE: Peritoneal metastasis from gastric cancer (GC) is generally considered incurable. Although conversion surgery is the preferred strategy, surgeons frequently encounter clinical scenarios requiring upfront surgery. Currently, objective criteria for predicting prognosis after upfront R0 gastrectomy remain undefined.
MATERIALS AND METHODS: This retrospective multicenter cohort study analyzed data from 792 patients derived from the PASS-META cohort and an independent validation dataset collected between 2014 and 2021. The final analysis included 80 patients with peritoneal oligometastasis (P1/P2) who underwent upfront R0 gastrectomy for risk stratification, and 632 controls who underwent R2 gastrectomy or no gastrectomy for survival comparison. A component-wise gradient-boosting survival model was developed and simplified into an 8-item risk scoring system.
RESULTS: The machine learning (ML) model demonstrated robust discrimination in external validation (concordance index, 0.811; 95% confidence interval, 0.677-0.955) and stratified patients into low- and high-risk groups with significantly different survival outcomes (log-rank P<0.001), independent of systemic chemotherapy compliance. Low-risk patients achieved a 5-year survival rate exceeding 30%, whereas high-risk patients showed survival rates comparable to those of patients who underwent R2 gastrectomy or no gastrectomy. The simplified 8-item risk groups showed high concordance with the ML model risk groups (F1-score, 0.975).
CONCLUSIONS: We developed and validated a prediction model and an 8-item risk scoring system that effectively stratified patients with peritoneal oligometastatic GC according to their prognosis after upfront R0 gastrectomy. Although prospective validation is warranted, this framework provides objective prognostic guidance that may support intraoperative decision-making, distinguishing patients with favorable long-term outcomes from those whose survival is comparable to that of noncurative approaches.
MATERIALS AND METHODS: This retrospective multicenter cohort study analyzed data from 792 patients derived from the PASS-META cohort and an independent validation dataset collected between 2014 and 2021. The final analysis included 80 patients with peritoneal oligometastasis (P1/P2) who underwent upfront R0 gastrectomy for risk stratification, and 632 controls who underwent R2 gastrectomy or no gastrectomy for survival comparison. A component-wise gradient-boosting survival model was developed and simplified into an 8-item risk scoring system.
RESULTS: The machine learning (ML) model demonstrated robust discrimination in external validation (concordance index, 0.811; 95% confidence interval, 0.677-0.955) and stratified patients into low- and high-risk groups with significantly different survival outcomes (log-rank P<0.001), independent of systemic chemotherapy compliance. Low-risk patients achieved a 5-year survival rate exceeding 30%, whereas high-risk patients showed survival rates comparable to those of patients who underwent R2 gastrectomy or no gastrectomy. The simplified 8-item risk groups showed high concordance with the ML model risk groups (F1-score, 0.975).
CONCLUSIONS: We developed and validated a prediction model and an 8-item risk scoring system that effectively stratified patients with peritoneal oligometastatic GC according to their prognosis after upfront R0 gastrectomy. Although prospective validation is warranted, this framework provides objective prognostic guidance that may support intraoperative decision-making, distinguishing patients with favorable long-term outcomes from those whose survival is comparable to that of noncurative approaches.